TriSalus Life Sciences, Inc. (TLSIW)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, TriSalus Life Sciences, Inc. reported revenue of $45.15M, up 53.4% from the prior year. The company ran a net loss, with a net margin of -86.9% and a gross margin of 84.6%. It held $35.33M in total assets against $69.19M in total liabilities.
Key ratios (FY2025)
84.6%
Gross margin
-59.7%
Operating margin
-86.9%
Net margin
+53.4%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $45.15M | $29.43M | $18.51M | $12.40M | — | — |
| Cost of Revenue | $6.96M | $4.10M | $2.60M | $2.26M | — | — |
| Gross Profit | $38.19M | $25.33M | $15.91M | $10.14M | — | — |
| Operating Income | -$26.95M | -$36.16M | -$54.48M | -$36.44M | -$3.04M | — |
| Net Income | -$39.23M | -$30.05M | -$59.36M | -$47.19M | $4.77M | — |
| EPS (Diluted) | $-1.84 | $-1.31 | $-6.77 | $-161.55 | — | — |
| Total Assets | $35.33M | $23.97M | $24.60M | $22.00M | $250.53M | $252.01M |
| Total Liabilities | $69.19M | $49.87M | $51.66M | $34.32M | $17.25M | $23.50M |
| Shareholders' Equity | -$33.86M | -$25.89M | -$27.07M | -$177.13M | -$129.60M | -$21.48M |
| Cash & Equivalents | $20.44M | $8.53M | $11.78M | $9.41M | $200.9K | $1.33M |
| Operating Cash Flow | -$18.01M | -$40.84M | -$50.58M | -$32.31M | -$1.74M | — |
| Capital Expenditures | $918.0K | $345.0K | $588.0K | $655.0K | — | — |
| Shares Outstanding | 50.00M | 31.28M | 26.41M | 347.9K | — | — |